Clinical trials: Healthy Volunteers Type 2 Diabetes
Diabetes Type 2
A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients
DM199 (recombinant human tissue kallikrein-1) is a new investigational compound that may eventually be used for the treatment of Diabetes Mellitus Type 2. This is the first time that this compound is being given to humans.
- Trial name
- NCT01845064
- Testing
- DM199
- Where
- Netherlands
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- DiaMedica Therapeutics Inc
Diabetes Mellitus, Type 2
A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption
The primary purpose of this study is to estimate the relative bioavailability and food effect of a PF-03882845 tablet as compared to a suspension formulation used in previous clinical studies.
- Trial name
- NCT01366287
- Testing
- PF-03882845
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Type 2 Diabetes
The Drug-drug Interaction of SHR3824 and SP2086
The purpose of the study is to investigate the potential interaction between multiple oral doses of SHR3824 and multiple oral doses of SP2086 in healthy adult volunteers.
- Trial name
- NCT02500485
- Testing
- SHR3824, SP2086
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects
This is 2-part study. The primary objective of Part 1 is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects.
- Trial name
- NCT07223333
- Testing
- PATAS Trifluoroacetate
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- AdipoPharma LLC
Type 2 Diabetes
The DDI Study of SP2086 and Simvastatin
The purpose of the study is to investigate the potential interaction between multiple oral doses of SP2086 and a single oral dose of Simvastatin in healthy adult volunteers.
- Trial name
- NCT02817243
- Testing
- SP2086, Simvastatin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Skin Samples of Diabetic Patients and Healthy Volunteers Collection
The main objective of this study is the Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new…
- Trial name
- NCT01349374
- Testing
- skin biopsy
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Diabetes Mellitus, Type 2
A Study Of PF-05175157 In Healthy Volunteers
The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-05175157 in healthy volunteers.
- Trial name
- NCT01274663
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters
This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers.
- Trial name
- NCT01819922
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Drug-drug Interaction Study(Lobeglitazone, Warfarin)
The purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and warfarin in healthy subjects.
- Trial name
- NCT02002611
- Testing
- Lobeglitazone, Warfarin
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus (T2DM)
Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers
This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the pharmacokinetics and safety after co-administration of L03RD1 and L03RD2 or administration of L03TD1 in healthy volunteers.
- Trial name
- NCT07533539
- Testing
- L03RD1, L03RD2, L03TD1
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Celltrion
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Type 2 Diabetes Mellitus
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
This study is designed to evaluate the safety and tolerability of a range of single oral doses of LGD-6972 in healthy subjects. Additionally, the study will characterize the Pharmacokinetic profile in healthy subjects under fed…
- Trial name
- NCT01919684
- Testing
- LGD-6972
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Ligand Pharmaceuticals
Type 2 Diabetes Mellitus
Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)
The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and Dapagliflozin from a 2.5-mg Saxagliptin/5-mg Dapagliflozin FDC tablet after oral administration relative to 2.5-mg Saxagliptin and 5-mg…
- Trial name
- NCT02060201
- Testing
- Saxagliptin, Dapagliflozin, Saxagliptin/Dapagliflozin FDC
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects
The purpose of this study was to investigate the effect of a high-fat meal on the levels of bexagliflozin in the blood in healthy subjects.
- Trial name
- NCT02820298
- Testing
- Bexagliflozin
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Theracos
Type 2 Diabetes Mellitus
Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil
To demonstrate the bioequivalence of saxagliptin and metformin in a saxagliptin, 5-mg/metformin extended-release (XR), 500-mg, fixed-dose combination (FDC) tablet with saxagliptin, 5-mg and metformin, 500-mg XR tablets…
- Trial name
- NCT01365091
- Testing
- Saxagliptin/metformin fixed-dose combination (FDC), Saxagliptin, Metformin extended-release (XR)
- Where
- Brazil
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382
A Phase 1 study to evaluate the effect of MEDI0382 on PK and PD of warfarin and esmolol in healthy subjects.
- Trial name
- NCT03347968
- Testing
- MEDI0382, Warfarin, Esmolol
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Diabetes Mellitus, Type 2, Liver Diseases
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic Disorders
This is a prospective, multicentric, non-treatment study to build and validate a portable, non-invasive smart breath analyzer that can screen underlying health issues using exhaled breath.
- Conditions
- Diabetes Mellitus, Type 2, Liver Diseases, Kidney Diseases, Lung Diseases
- Trial name
- RESPYR-SBA (NCT07646015)
- Where
- India
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Respyr
Type II Diabetes Mellitus
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects
This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects
- Trial name
- CKD-371 (NCT05544214)
- Testing
- CKD-371
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus
DS-1150b is being developed by Daiichi Sankyo for the treatment of Type 2 Diabetes Mellitus. This is a Phase I, single-blind (subjects and principal investigator blinded, Sponsor unblinded), placebo-controlled, randomized…
- Trial name
- NCT02004678
- Testing
- DS-1150b
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo